Table 3 Summary of mRECIST and EASL responses
From: Imaging of hepatocellular carcinoma and image guided therapies - how we do it
| Â | mRECIST | EASL |
|---|---|---|
Complete Response | Disappearance of any intratumoral arterial enhancement in all target lesions (up to 2 measurable liver lesions) | Disappearance of any intratumoral arterial enhancement in all measurable arterial enhancing liver lesions |
Partial Response | Decrease >30% in the sum of longest diameters of viable target lesions | Decrease >50% in the sum of the product of bidimensional diameters of viable target lesions |
Progressive Disease | Increase >20% in the sum of longest diameters of viable target lesions | Increase >25% in the sum of the diameters of viable target lesions |
Stable Disease | None of the above | None of the above |